Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Dogwood Therapeutics, Inc. (DWTX)

Compare
17.55
+0.15
+(0.86%)
As of January 28 at 9:34:37 AM EST. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DWTX

Recent News: DWTX

View More
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
GlobeNewswire 6 days ago
DWTX: Interim Data for Phase 2b Trial in 4Q25…

DWTX: Interim Data for Phase 2b Trial in 4Q25…
Zacks Small Cap Research 12 days ago
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
GlobeNewswire 14 days ago
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire 16 days ago
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
GlobeNewswire 30 days ago
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…
Zacks Small Cap Research 30 days ago
Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today
TipRanks last month
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire last month
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
GlobeNewswire last month
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
GlobeNewswire 2 months ago
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
GlobeNewswire 4 months ago
View More

Related Tickers

MURA Mural Oncology plc
2.5198
+4.12%
 
SKYE Skye Bioscience, Inc.
1.5507
-1.85%
 
CDT Conduit Pharmaceuticals Inc.
0.6231
-20.13%
 
THTX Theratechnologies Inc.
2.5800
+0.39%
 
KTTA Pasithea Therapeutics Corp.
1.3800
+0.73%
 
PHIO Phio Pharmaceuticals Corp.
2.9000
+7.41%
 
BCTX BriaCell Therapeutics Corp.
4.5000
+0.45%
 
MTVA MetaVia Inc.
0.6843
-6.55%
 
ELAB PMGC Holdings Inc.
2.5800
0.00%
 
PRTG Portage Biotech Inc.
7.60
+12.59%